The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: Results from an analysis of two randomized controlled trials in early diffuse scleroderma

Rheumatology

Volumn 43, Issue 4, 2004, Pages 472-478

  Sultan, N ^b   Pope, Janet E ^b,c   Clements, P J ^a   Furst, D E ^d   Siebold, J R ^d   Wong, W K ^d   Bellamy, N ^d   Mayes, M ^d   Baron, M ^d   White, B ^d   Ellman, M ^d   Wigley, F ^d   Carette, S ^d   Weismann, M H ^d   Smith, C D ^d   Barr, W ^d   Chalmers, I M ^d   Moreland, L W ^d   Medsger Jr , T A ^d   Hong, P ^d   Steen, V ^d   O'Hanlon, D ^d   Martin, R W ^d   Kaminska, E ^d   Collier, D ^d   Markland, J ^d   Lally, E ^d   Sibley, J ^d   Varga, J ^d   Catoggio, L ^d   Weiner, S ^d   Andrews, B ^d   Abeles, M ^d   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c ST JOSEPH S HEALTH CENTRE   (Canada)

^d NONE

Author keywords

Early diffuse scleroderma; Good outcome; HAQ; Prognosis

Indexed keywords

METHOTREXATE; PENICILLAMINE;

ADULT; AGE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISABILITY; GENDER; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; PAIN ASSESSMENT; PREDICTION; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SKIN MANIFESTATION; SYSTEMIC SCLEROSIS;

DERMATOLOGIC AGENTS; DISABILITY EVALUATION; FEMALE; HEALTH STATUS INDICATORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; MIDDLE AGED; PENICILLAMINE; PROGNOSIS; QUESTIONNAIRES; SCLERODERMA, DIFFUSE; TREATMENT OUTCOME;

EID: 11144356295     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keh070     Document Type: Article

References (17)

1. LeRoy EC, Black C, Fleischmajer R el at. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-4.
2. Medsger TA Jr, Silman AJ, Steen VD et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999;26:2159-67.
3. Steen VD, Medsger TA Jr. Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum 2001;44:2828-35.
4. Clements PJ, Lachenbruch PA, Seibold JR et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281-5.
5. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
6. Hawley DJ, Wolfe F. Sensitivity to change of the Health Assessment Questionnaire (HAQ) and other clinical and health status measures in rheumatoid arthritis: results of short-term clinical trials and observational studies versus long-term observational studies. Arthritis Care Res 1992;5:130-6.
7. Wolfe F, Hawley DJ. The longterm outcomes of rheumatoid arthritis: Work disability: a prospective 18-year study of 823 patients. J Rheumatol 1998;25:2108-17.
8. Clements PJ, Wong WK, Hurwitz EL et al. Correlates of the disability index of the Health Assessment Questionaire: a measure of functional impairment in systemic sclerosis. Arthritis Rheum 1999;42:2372-80.
9. Clements PJ, Wong WK, Hurwitz EL et al. The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. Arthritis Rheum 2000;44:653-61.
10. Clements PJ, Furst DE, Wong W-K et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999;42:1194-203.
11. Pope J, Furst D. A randomized controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001;44:1351-8.
12. Subcommittee for scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-91.
13. Furst DE, Clements PJ, Hillis S et al. Immunosuppression with chlorambucil, versus placebo, for scleroderma: results of a three-year, parallel, randomized, double-blind study. Arthritis Rheum 1989;32:584-93.
14. Kaheleh MB, Sultany GL, Smith EA, Huffstutter JE, Loadholt CB, LeRoy EC. A modified scleroderma skin scoring method. Clin Exp Rheumatol 1986;4:367-9.
15. Clements PJ, Hurwitz EL, Wong WK et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis. Arthritis Rheum 2000;43:2445-54.
16. Moreland LW, Schiff MH, Baumgartner SW. Etanercept therapy in rheumatoid arthritis. A randomized controlled trial. Ann Intern Med 1999;130:478-86.
17. Pope JE, Bellamy N. Sample size calculations in scleroderma: a rational approach to choosing outcome measurements in scleroderma trials. Clin Invest Med 1995;18:1-10.